GlassScriptPhysician profile
Rene Alonzo
NPI 1760977425
$4,403.87
in general payments reported to CMS, 2019-2025
35 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2022: $400 · 2023: $863 · 2024: $1,691 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,835 · Education: $23.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,835.34 |
| Education | $23.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $561.80 | 2023-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $311.83 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $267.81 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $267.80 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $263.26 | 2022-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $253.09 | 2022-2025 | |
| Gilead Sciences, INC. | $241.25 | 2022-2025 | Yeztugo |
| Lundbeck LLC | $236.52 | 2023-2025 | Rexulti, Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.24 | 2023-2025 | Jardiance |
| Indivior INC. | $168.71 | 2023-2025 | Sublocade |
| Stryker Corporation | $145.17 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.57 | 2022-2025 | |
| Amgen INC. | $126.10 | 2022-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.48 | 2024-2025 | Caplyta |
| Boston Scientific Corporation | $99.11 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $93.87 | 2022-2024 | Vivitrol |
| Mylan Specialty L.P. | $90.37 | 2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.47 | 2023-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $79.83 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $76.25 | 2022-2024 | Trintellix, Gattex |
| Insulet Corporation | $67.84 | 2023-2025 | Omnipod |
| Phathom Pharmaceuticals, INC. | $62.22 | 2024 | Voquezna |
| Medtronic, INC. | $60.68 | 2023 | Nellcor, Intellis Adaptivestim |
| Dexcom, INC. | $54.00 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $51.41 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $48.80 | 2025 | Spravato |
| Ethicon US, LLC | $44.54 | 2025 | Enseal, Harmonic, Echelon; Endopath |
| Edwards Lifesciences Corporation | $38.49 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Vanda Pharmaceuticals INC. | $37.41 | 2025 | Fanapt |
| Verona Pharma, INC. | $25.46 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $25.42 | 2025 | Yupelri |
| Abbott Laboratories | $21.32 | 2024 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $18.49 | 2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $15.87 | 2023 | |
| Sanofi Pasteur INC. | $13.39 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Alonzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.